The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01D | Cytotoxic antibiotics and related substances | |
| 4 | L01DB | Anthracyclines and related substances | |
| 5 | L01DB01 | Doxorubicin |
| Active Ingredient | Description | |
|---|---|---|
| Doxorubicin |
Doxorubicin is a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ADRIAMYCIN Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| CAELYX Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| CELDOXOME PEGYLATED LIPOSOMAL Concentrate for dispersion for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| DOXORUBICIN Concentrate for solution for infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| DOXORUBICIN Teva Sol. | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| ZOLSKETIL Concentrate for dispersion for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
